Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xinggelietin (DC407) in Chinese adults with type 2 diabetes mellitus and fatty liver disease
CTR20221874Phase 2Completed
- Sponsor
- Cisen Pharmaceutical Co., Ltd.
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of singletine in type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Cisen Pharmaceutical Co., Ltd.. Started Aug 2022; status: completed.
02
Drugs
singletine
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on CTR20221874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221874.